siRNA for inhibiting HMGB1 gene, stable nucleic acid lipid nanoparticle containing siRNA, and application of siRNA and stable nucleic acid lipid nanoparticle

A lipid nanoparticle, stable technology, applied in the field of medicine, to achieve the effects of improving utilization rate, inflammation and remission of bullous steatosis, and stable process
CN111363746AActive Publication Date: 2020-07-03EAST CHINA NORMAL UNIV
2 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
EAST CHINA NORMAL UNIV
Publication Date
2020-07-03

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides siRNA for inhibiting an HMGB1 gene, a stable nucleic acid lipid nanoparticle containing the siRNA, and an application of the siRNA and the stable nucleic acid lipid nanoparticle. The positive-sense strand of an siRNA molecule is SEQ ID NO:1, and the antisense chain is SEQ ID NO:2. The technical effects are as follows that the siRNA aiming at the HMGB1 is encapsulated in thestable nucleic acid lipid nanoparticle, so that the siRNA is prevented from being degraded by in-vivo enzymes; the prepared nanoparticle has a significant anti-inflammatory effect; and the siRNA aiming at the HMGB1 can be targeted and delivered to liver macrophages for release to enhance the anti-inflammatory effect, so that non-alcoholic steatohepatitis (NASH) can be better treated.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to siRNA capable of effectively silencing the expression of HMGB1 in a NASH model, stable nucleic acid lipid nanoparticles loaded with siRNA and applications thereof, belonging to the technical field of medicine. Background technique

[0002] In Western countries, nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. NAFLD includes simple fatty liver, nonalcoholic steatohepatitis (NASH) and its related fibrosis and cirrhosis. Even liver cancer. NASH is a more aggressive form of fatty liver disease that can progress to cirrhosis and complications of cirrhosis, including liver failure and hepatocellular carcinoma, and is expected to be the most common indication for liver transplantation over the next decade. Unlike alcoholic hepatitis, patients with NASH have no history of past alcohol use and are histologically characterized by steatosis, inflammation, and hepatocellular injury or associated liver fib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More